Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, multi-center, open-label extension study in ambulant boys with DMD who
have completed the 48-week treatment period of either viltolarsen or placebo in Study
NS-065/NCNP-01-301.